Metastatic Neoplasm Clinical Trial
Official title:
Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN) Multicenter Randomized Phase II Clinical Trial
The purpose of this study is to compare three types of radiation therapy for cancer that has spread to the spine. The two types of radiation therapy used in this trial are External Beam Radiation Therapy (EBRT) and Stereotactic Body Radiation Therapy (SBRT). EBRT delivers tightly targeted radiation beams from outside the body. SBRT is a specialized type of radiation therapy that allows high doses of radiation to small targets. This study will include standard dose SBRT and higher dose SBRT. Each participant will be randomly assigned to either EBRT, standard dose SBRT, or higher dose SBRT.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | December 31, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant must have histologic confirmation of malignancy. Spinal metastatic disease must be confirmed by imaging. - Participant must have received no prior therapies for this disease. Prior therapy includes previous radiation therapy encompassing the anatomic site to be treated with spine SBRT. This includes any previous radiation therapy where the treatment field overlaps with the anatomic site to be treated with spine SBRT (even if that previous radiation therapy was not for treatment of spinal disease). Systemic radiation therapy for metastatic disease such as Pluvicto also counts as previous radiation therapy. - Age >18 years. This study requires informed consent by the participant; as children are not able to perform this without parental approval, Participant < age 18 are excluded from this study. - Life expectancy of= 3 months, in the opinion of and as documented by the investigator. - Participant must have a worst pain score < 2 of 10 according to the Brief Pain Inventory - Participant must have no intention of changing pain medications on the first day of SBRT - Participant must have a Spinal Instability score (SINS) = 12 - Participant must be a spine SBRT candidate per Radiation Oncology - Participant must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Participant receiving any other investigational agents. - Participant with prognosis less than 3 months will be excluded from this clinical trial because of their poor prognosis and decreased likelihood to meet the primary endpoint - Participant with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant or nursing Participant are excluded due to toxicity of radiation therapy. - Participant is unable to receive MRI of the spine - Participant has a Spinal Instability in Neoplasia score (SINS) = 12 - Participant has received previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field - Participant has more than 3 consecutive vertebral bodies in the SBRT treatment volume - Participant is not an SBRT candidate per radiation oncology discretion - Participant has a known primary and has an estimated median survival= 3 months - Participant has an unknown primary - Participant has a Brief Pain Inventory score > 2 - Participant has received previous radiation therapy involving the intended SBRT treatment field - Participant has received previous spinal surgical procedure involving the SBRT target volume. Biopsy is not considered a previous spinal surgical procedure. - Participant has neurological deficits from malignant cauda equina compression or epidural spinal cord compression |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain freedom based on BPI score difference | Freedom from pain at 3 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI. | 3 months | |
Secondary | Pain freedom based on BPI score difference | Freedom from pain at 6 months defined as pain freedom following spine SBRT/EBRT per the Brief Pain Inventory (BPI), which is a scale of 1-10. The complete response for pain freedom is defined as a "worst" pain score of 0 on the BPI. Partial pain freedom is defined as a "worst" pain score of 2 points on the BPI. | 6 months | |
Secondary | Local Control | 6-month local control, defined as an actuarial 6-month rate of any new, recurrent or progressing (as defined by SPINOcriteria) tumor within the planning target volume on any post-treatment MRI by 6 months. Follow-up MRIs will be fused with the planning scan for this assessment | 6 months | |
Secondary | Vertebral compression fracture rate | 6-month vertebral compression fracture rate, assessed by post-treatment MRI by 6 months | 6 months | |
Secondary | Survival | Overall participant survival | 6 months | |
Secondary | Vertebral compression fracture rate | 12-month vertebral compression fracture rate, assessed by post-treatment MRI at 12 months | 12 months | |
Secondary | Demographic disparities | Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 3 months | 3 months | |
Secondary | Demographic disparities | Demographic disparities (by race, ethnicity, gender identity, sexual orientation, insurance status) following spine SBRT/EBRT access and outcomes at 6 months | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
Terminated |
NCT02566421 -
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
|
N/A | |
Completed |
NCT01606033 -
Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating
|
N/A | |
Terminated |
NCT04418661 -
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00525057 -
Dalteparin in Preventing DVT in Participants With Cancer
|
N/A | |
Terminated |
NCT03871348 -
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02775292 -
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
|
Phase 1 | |
Active, not recruiting |
NCT05103358 -
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
|
Phase 2 | |
Recruiting |
NCT02560311 -
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
|
N/A | |
Completed |
NCT02492711 -
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
|
Phase 3 |